Adaptimmune Therapeutics Plc. (ADAP) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Adaptimmune Therapeutics Plc faces a significant business risk concerning its compliance with the Nasdaq Global Select Market’s listing requirements. The company’s American Depositary Shares (ADSs) must maintain a minimum closing bid price of $1.00, a condition they previously failed to meet for 30 consecutive days, resulting in a deficiency notice in August 2023. Although they regained compliance by February 2024, there’s no assurance against future noncompliance, which could lead to delisting. Delisting would negatively affect the ADSs’ liquidity, market price, and the company’s capacity to secure capital.
The average ADAP stock price target is $3.75, implying 115.52% upside potential.
To learn more about Adaptimmune Therapeutics Plc.’s risk factors, click here.
